MorphoSys' Pelabresib Improves All Four Hallmarks of Myelofi

11.12.2023 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve ... Seite 1

Related Keywords

, Raajitk Rampal , Myeloproliferative Neoplasms Program , Memorial Sloan Kettering Cancer Center , Hematologic Malignancies , Memorial Sloan , Kettering Cancer , Morphosys Aktie ,